Serun Institute of India (SII) has begun manufacturing the United States (US) biotech firm Codagenix Inc's potential COVID-19 vaccine, the American company said.
Codagenix also said that it expected to start early-stage human trials of the vaccine candidate by the end of this year in the United Kingdom (UK).
The vaccine candidate CDX-005 by Codagenix is delivered intranasally rather than via an injection.
The SII is the world's largest vaccine manufacturer by quantity of doses produced. It is already working on a number of vaccine candidates against the novel coronavirus -- SarsCoV-2.
One of the most prominent and talked about vaccine candidate the SII is involved with is UK's Covishield, developed by AstraZeneca and Oxford University. The SII may also be its mass-production partner as it is in the last stages of trials.
Apart from conducting trials and potentially mass-producing, the institute is also working to develop its own vaccine candidate.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 999/year is the best way you can support our efforts.